BioDelivera
Programmable drug delivery precisely targets only diseased cells
BioDelivera has developed proprietary GCV™, a drug delivery platform designed to travel through the body and selectively target diseased cells while sparing healthy ones. GCVs can carry genetic medicines, DNA, RNA, small molecules, or combinations of these at the same time. BioDelivera has demonstrated efficacy in tumors, muscle, and brain and is expanding to additional tissues. The company’s mission is to enable cures for every patient, across every disease.
- Website
- biodelivera.com
- City
- San Francisco
- Country
- United States
- YC batch
- Fall 2026
- Team
- 2 people
- Stage
- Early stage
- AI-native
- No
More Health & bio in San Francisco
Innovaccer$1.3bn
Indian digital healthcare company.
Thatch$1bn
Health benefits. Valued at $1bn (September 2026).
Chan Zuckerberg BiohubLab
Nonprofit research network building virtual cell models.
AthelasHiring
Extensible, Integrated Technology that Simplifies Health Systems
ClipboardHiring
Every shift, Covered.
Benchling
Unlocking the power of biotech with modern software for modern science
Claim this profile
Free and instant: prove you run biodelivera.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to BioDelivera across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with BioDelivera's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
